Synthetic lethality between PAXX and XLF in mammalian development

  1. Stephen P. Jackson1,2,3
  1. 1Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge CB2 1QN, United Kingdom;
  2. 2Wellcome Trust Sanger Institute, Cambridge CB10 1HH, United Kingdom;
  3. 3Department of Biochemistry, University of Cambridge, Cambridge CB2 1GA, United Kingdom;
  4. 4Department of Immunology, University of Cambridge, Cambridge CB2 1GA, United Kingdom;
  5. 5Department of Genomes and Genetics, Institut Pasteur, 75015 Paris, France;
  6. 6AstraZeneca, Cambridge CB4 0FZ, United Kingdom;
  7. 7Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom;
  8. 8Cancer Research UK/Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford OX3 7DQ, United Kingdom
  1. Corresponding authors: s.jackson{at}gurdon.cam.ac.uk, andrew.blackford{at}oncology.ox.ac.uk
  • 9 Present address: Horizon Discovery, Cambridge Research Park, Waterbeach, Cambridge CB25 9TL, UK.

Abstract

PAXX was identified recently as a novel nonhomologous end-joining DNA repair factor in human cells. To characterize its physiological roles, we generated Paxx-deficient mice. Like Xlf−/− mice, Paxx−/− mice are viable, grow normally, and are fertile but show mild radiosensitivity. Strikingly, while Paxx loss is epistatic with Ku80, Lig4, and Atm deficiency, Paxx/Xlf double-knockout mice display embryonic lethality associated with genomic instability, cell death in the central nervous system, and an almost complete block in lymphogenesis, phenotypes that closely resemble those of Xrcc4−/− and Lig4−/− mice. Thus, combined loss of Paxx and Xlf is synthetic-lethal in mammals.

Keywords

Footnotes

  • Received July 23, 2016.
  • Accepted September 21, 2016.

This article, published in Genes & Development, is available under a Creative Commons License (Attribution 4.0 International), as described at http://creativecommons.org/licenses/by/4.0/.

| Table of Contents
OPEN ACCESS ARTICLE

Life Science Alliance